Novan Announces Late-Breaking Abstract Accepted for Presentation at American Academy of Dermatology’s (AAD) 2022 Annual Meeting
DURHAM, N.C., March 24, 2022 (GLOBE NEWSWIRE) — Novan, Inc. (“the Company” or “Novan”) (Nasdaq:…
Month: March 2022
Marrone Bio Expands Biological Seed Treatment Collaboration for Row Crops
Company poised for continued growth in a $6+ billion market¹ RALEIGH, N.C., March 24, 2022…
Celsion Corporation to Hold Year-End 2021 Financial Results and Business Update Conference Call on Thursday, March 31, 2022
LAWRENCEVILLE, N.J., March 24, 2022 (GLOBE NEWSWIRE) — Celsion Corporation (NASDAQ: CLSN), a clinical-stage development company…
Revelation Biosciences Inc. Outlines Details on the Upcoming Data Analysis for Phase 2b Viral Challenge Study to Assess Efficacy of Intranasal REVTx 99a for the Prevention of H3N2 Influenza Infection
-Primary endpoint analysis expected early Q2 2022- -Final data expected Q2 2022- SAN DIEGO, March…
SCYNEXIS to Report Fourth Quarter and Full Year 2021 Financial Results and Provide a Business Update
JERSEY CITY, N.J., March 24, 2022 (GLOBE NEWSWIRE) — SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology…
Palisade Bio (Nasdaq: PALI) to Participate in the 2022 Virtual Growth Conference Presented by Maxim Group and Hosted by M-Vest
CARLSBAD, Calif., March 24, 2022 (GLOBE NEWSWIRE) — Palisade Bio, Inc. (Nasdaq: PALI), a clinical…
HCW Biologics to Present at 2022 Virtual Growth Conference Sponsored by the Maxim Group and M-Vest
Founder and CEO, Hing C. Wong, Ph.D., to be guest at “Fireside Chat” MIRAMAR, Fla.,…
Monopar Therapeutics Reports Fourth Quarter and Full-Year 2021 Financial Results and Recent Program Developments
Validive® Phase 2b/3 VOICE Trial Continues Adding Sites in the U.S. and Europe Camsirubicin Phase…
Revolo Biotherapeutics to Participate at SVB Leerink Biopharma Private Company Connect
NEW ORLEANS and LONDON, March 24, 2022 (GLOBE NEWSWIRE) — Revolo Biotherapeutics (“Revolo Bio” or…
Immutep Announces Publication of TACTI-002 Abstract at ESMO’s European Lung Cancer Congress 2022
New interim data from TACTI-002 (Part B) evaluating the combination of efti and pembrolizumab in…
VistaGen to Participate in Fireside Chat at Maxim Group 2022 Virtual Growth Conference
SOUTH SAN FRANCISCO, Calif., March 24, 2022 (GLOBE NEWSWIRE) — VistaGen Therapeutics, Inc. (Nasdaq: VTGN)…
Longeveron Presents at Second Euro-Geroscience Conference
Longeveron management presents live at the Second Euro-Geroscience Conference and at a pre-meeting task force…
BioCardia to Host 2021 Financial Results and Corporate Update Conference Call on March 29, 2022
SUNNYVALE, Calif., March 24, 2022 (GLOBE NEWSWIRE) — BioCardia®, Inc. [NASDAQ:BCDA], a developer of cellular…
Impel NeuroPharma Announces Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update
Trudhesa™ Exceeds Fourth Quarter 2021 Prescription Guidance; Strong Launch Continues Into 2022 Demonstrated by 157%…
Surrozen Reports Fourth Quarter and Full Year 2021 Financial Results
On Track to Initiate Phase 1 Clinical Trials in Healthy Volunteers for SZN-1326 and SZN-043…
Ocuphire Announces Financial Results for the Fourth Quarter and Year Ended December 31, 2021 and Provides Corporate Update
Building Momentum with Completion of Patient Enrollment in 4 Late-Stage Trials Multiple Late-Stage Clinical Trial…
ContraFect Reports Fourth Quarter 2021 and Full Year 2021 Financial Results and Provides Business Update
Phase 3 DISRUPT study enrollment continues on course towards conducting interim futility analysis as anticipated…
Reviva Pharmaceuticals Holdings, Inc. Interview to Air on Bloomberg U.S. on the RedChip Money Report®
CUPERTINO, Calif., March 24, 2022 (GLOBE NEWSWIRE) — Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH), (“Reviva” or…
Dante Labs establishes the first of its Regional Medical Genomics Boards in Europe made of national and multinational world leaders in genomics
NEW YORK, March 24, 2022 (GLOBE NEWSWIRE) — Dante Labs, a global leader in genomics…
Mydecine Receives Conditional IRB Approval for Phase 2b Smoking Cessation Study
Clinical trial programs advance to further assess psychedelic-assisted psychotherapy utilizing lead drug candidate MYCO-001 DENVER,…